ADIL · Adial Pharmaceuticals Inc

-

Please sign in to comment on ADIL

1 Comment

Admin

4 years, 1 month ago

Adial Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 17.4% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Adial Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 68.5% to $-3M since the same quarter in the previous year.

Finally, its free cash flow fell by 49.1% to $-3M since the same quarter in the previous year.

Based on the above factors, Adial Pharmaceuticals, Inc gets an overall score of 2/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	NASDAQ
CurrencyCode	USD
ISIN	US00688A1060

PE Ratio	None
Target Price	6.5
Beta	1.22
Market Cap	5M
Dividend Yield	None

ABOUT

Adial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.

ADIL · Adial Pharmaceuticals Inc

-

Adial Pharmaceuticals Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Adial Pharmaceuticals Inc using a moving average strategy